SCHEMBL16295661

SCHEMBL16295661

CC(C)(C)OC(=O)CCNC(=O)C(Cc1ccc(-c2ncc(C(=O)O)cn2)cc1)NC(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ GCGR P47871 4/20 0.43
▸ ADCY6 O43306 3/20 0.43
▸ ADCY3 O60266 3/20 0.43
▸ ADCY9 O60503 3/20 0.43
▸ ADCY5 O95622 3/20 0.43
▸ ADCY8 P40145 3/20 0.43
▸ ADCY7 P51828 3/20 0.43
▸ ADCY2 Q08462 3/20 0.43
▸ ADCY1 Q08828 3/20 0.43
▸ ADCY4 Q8NFM4 3/20 0.43
▸ CTSS P25774 8/20 0.43
▸ CTSK P43235 8/20 0.43
▸ CTSB P07858 3/20 0.43
▸ KIFC1 Q9BW19 2/20 0.42
▸ XDH P47989 1/20 0.42
▸ KMT2A Q03164 1/20 0.41
▸ KLKB1 P03952 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ NR1H4 Q96RI1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16295659 1.00 L3MBTL1 (0.48) L3MBTL1GCGRADCY6ADCY3ADCY9
SCHEMBL22384053 0.91 L3MBTL1 (0.46) L3MBTL1GCGRADCY6ADCY3ADCY9
SCHEMBL16305641 0.91 L3MBTL1 (0.46) L3MBTL1GCGRADCY6ADCY3ADCY9
SCHEMBL16305638 0.90 L3MBTL1 (0.46) L3MBTL1GCGRADCY6ADCY3ADCY9
SCHEMBL16375227 0.88 L3MBTL1 (0.43) L3MBTL1GCGRADCY6ADCY3ADCY9
SCHEMBL16295278 0.86 ROCK2 (0.49) XDHKMT2AEPHX2NR1H4
SCHEMBL16295279 0.86 ROCK2 (0.49) XDHKMT2AEPHX2NR1H4
SCHEMBL22384055 0.85 L3MBTL1 (0.42) L3MBTL1GCGRADCY6ADCY3ADCY9
SCHEMBL22384060 0.84 L3MBTL1 (0.45) L3MBTL1CTSSCTSKCTSBKIFC1
SCHEMBL22384056 0.83 L3MBTL1 (0.41) L3MBTL1GCGRADCY6ADCY3ADCY9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008056-B1 NOVEL GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-12-09 — — EP disclosed
EP-3008056-B1 NOVEL GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-12-09 — — EP disclosed
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
CN-109867630-A - 1 receptor modulators of novel glp-1 赛尔基因第二国际有限公司 2019-06-11 — — CN disclosed
US-10259823-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2019-04-16 — — US disclosed
CN-105593225-B novel GLP-1 receptor modulators 赛尔基因第二国际有限公司 2019-04-16 — — CN disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-9598430-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-03-21 — — US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-07-28 — — US disclosed
EP-3008056-A1 NOVEL GLP-1 RECEPTOR MODULATORS Receptos, Inc. (US) 2016-04-20 — — EP disclosed
US-9260427-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2016-02-16 — — US disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed
WO-2014201172-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2014-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885GCGR 4/4885ADCY6 323/4885
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885GCGR 4/4885ADCY6 323/4885
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885GCGR 4/4885ADCY6 323/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885GCGR 4/4885ADCY6 323/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR L3MBTL1 579/4885GCGR 3/4885ADCY6 411/4885
US-10259823-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR L3MBTL1 579/4885GCGR 3/4885ADCY6 411/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885GCGR 4/4885ADCY6 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback